How big is the Eosinophilic Esophagitis Market | Size & Forecast 2025

Q: What is contributing to the growth of the eosinophilic esophagitis market?

The market is growing due to rising prevalence, improved diagnostics, and increasing healthcare awareness around gastrointestinal diseases.

Q: What are the major challenges in this market?

High treatment costs, underdiagnosis, and limited approved therapies continue to challenge market growth.

Q: Which treatment segment dominates the eosinophilic esophagitis market?

Topical corticosteroids currently dominate, but biologics are rapidly emerging as a key segment.

Q: What will the EoE market be worth by 2031?

The eosinophilic esophagitis market is expected to surpass USD 1.6 billion by 2031.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6448

Publication Date: Jul 2025

How Big Is the Eosinophilic Esophagitis Market?

According to 6Wresearch internal database and industry insights, the Global eosinophilic esophagitis market was valued at USD 0.8 billion in 2024 and is projected to reach over USD 1.6 billion by 2031, growing at a CAGR of 11.20% during the forecast period.

This growth can be attributed to increased disease awareness, advances in biologic therapies such as monoclonal antibodies, and growing regulatory approvals for targeted treatment options. In addition to this, pediatric and adult populations are showing heightened prevalence, necessitating both long-term disease management and new pharmaceutical interventions.

Key Growth Factors of the Eosinophilic Esophagitis Market

Increasing incidence and improved recognition of EoE as a distinct clinical condition
Development of biologic drug pipelines specifically targeting eosinophilic inflammation
Bourgeoning pediatric patient pool with chronic esophageal inflammation
Supportive FDA approvals accelerating innovative treatment options
There has been increased use of endoscopy and biopsy to support accurate diagnoses
Collaborative research efforts enhancing disease understanding and patient outcomes

Eosinophilic Esophagitis Market Trends

Eosinophilic Esophagitis Market is experiencing a transition toward targeted biological therapies that address the root causes of eosinophilic inflammation rather than just symptom relief. There is a notable shift from corticosteroid-based therapies to IL-13 and IL-5 pathway inhibitors, as well as a rise in patient-centric care involving dietary management and improved diagnostic guidelines. Increasing collaboration between pharmaceutical companies and academic research institutions is further shaping the future treatment landscape.

Emerging Developments in the Eosinophilic Esophagitis Market

Emerging developments in the Eosinophilic Esophagitis Industry include the FDA approval of the first dedicated treatment which has opened pathways for novel biologics and biosimilars. Clinical trials are now focusing on non-steroidal oral treatments and microbiome-based solutions. Additionally, healthcare providers are investing in advanced esophageal imaging technologies and diagnostic tools to detect early-stage EoE, which may reduce long-term complications and hospitalizations.